Abstract | BACKGROUND: METHODS: RESULTS: The review identified 93 patients, 31 of whom did not experience a neutropenic event. Of the 62 who experienced neutropenia, 18 were managed with g-csf support, and 44, with reductions or delays in dose. Compared with patients experiencing a neutropenic episode not treated with g-csf, those treated with g-csf experienced a nonsignificant increase in time to event [progression or death: hazard ratio (hr): 1.37; 95% confidence limits (cl): 0.72, 2.61], but compared with patients not having a neutropenic episode, the same patients experienced a significant increase in time to event (hr: 2.07; 95% cl: 1.03, 4.15). CONCLUSIONS: In patients who experienced neutropenia, g-csf did not have a statistically significant impact on survival. Time to event was prolonged in g-csf-treated patients compared with patients who did not experience neutropenia.
|
Authors | A Amadio, R Burkes, T Bailie, M McLean, B Coleman |
Journal | Current oncology (Toronto, Ont.)
(Curr Oncol)
Vol. 21
Issue 1
Pg. e52-61
(Feb 2014)
ISSN: 1198-0052 [Print] Switzerland |
PMID | 24523621
(Publication Type: Journal Article)
|